SCHEDULE: RTW Investments Discloses Stake in Candel Therapeutics

RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Candel Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• RTW Investments, LP, an investment adviser, and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer, have filed a joint Schedule 13G.
• This filing indicates their beneficial ownership of 6,422,018 shares of Candel Therapeutics, Inc. common stock.
• This ownership represents 8.8% of the company's outstanding common stock as of March 5, 2026.
• The shares are held by RTW Funds, which are managed by RTW Investments.
• The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates institutional interest and confidence from RTW Investments, but provides no operational or financial performance data.

Positives

• RTW Investments, a significant investment entity, has taken a notable stake in Candel Therapeutics, potentially signaling confidence in the company's prospects.
• The disclosure of an 8.8% ownership stake by a professional investment firm can be interpreted as a positive signal to the market.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• There is no indication of any adverse events or performance issues within the provided document.

Risks

• The filing does not explicitly mention any risks. However, as with any investment, there are inherent market risks associated with holding shares in a publicly traded company.
• The concentration of ownership by RTW Investments could potentially lead to increased volatility if they decide to divest a significant portion of their holdings.

Future Outlook

The filing does not contain any forward-looking statements or specific future outlook for Candel Therapeutics, Inc. It is purely a disclosure of beneficial ownership.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like RTW Investments in biotechnology companies, such as Candel Therapeutics, often indicate a belief in the company's pipeline or market potential, especially in a sector driven by innovation and clinical trial progress.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a positive sign, potentially leading to increased investor interest and share price stability or appreciation.
• Management: May see the stake as a vote of confidence, but also potentially increased scrutiny from a significant shareholder.
• Creditors: Unlikely to be directly impacted by this ownership disclosure, as it does not relate to the company's debt obligations.

Next Steps

• RTW Investments, LP and Roderick Wong, M.D. will file amendments to this statement on Schedule 13G if any material changes occur in their beneficial ownership.
• Candel Therapeutics, Inc. will continue its operations and report future financial and operational results as per its regular SEC filing schedule.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not contain information about Candel Therapeutics' operational performance, financial results, or future prospects. While the acquisition of an 8.8% stake by RTW Investments is a positive signal of institutional interest, it is insufficient on its own to warrant a buy or sell recommendation. A 'hold' recommendation is appropriate pending further information on the company's performance and strategy.

Keywords

Candel Therapeutics, RTW Investments, Schedule 13G, Beneficial Ownership, Investment Adviser, Roderick Wong, Common Stock, SEC Filing, Securities Exchange Act